Evidence map›Paper›PMID 36513909›Full record

ReviewCNS drugs2023

Estimating Risk of Antidepressant Withdrawal from a Review of Published Data.

Mark Abie Horowitz, Adele Framer, Michael P Hengartner, Anders Sørensen, David Taylor

Open access · hybridAbstract readReview
In one paragraph

Review in CNS drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 5 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Antidepressants for low back pain and spine-related leg pain.The Cochrane database of systematic reviews · 2025
    Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. The role of empathy in antidepressant withdrawal.Therapeutic advances in psychopharmacology · 2025
    Article
  16. Article
  17. Acceptability and optimisation of resources to support antidepressant cessation: a qualitative think-aloud study with patients in Australian primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2024
    Article
  18. The lived experience of withdrawal from Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants: A qualitative interview study.Health expectations : an international journal of public participation in health care and health policy · 2024
    Article
  19. Mechanisms of SSRI Therapy and Discontinuation.Current topics in behavioral neurosciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Mark Abie HorowitzNorth East London NHS Foundation Trust, Goodmayes Hospital, Ilford, UK. m.horowitz@ucl.ac.uk.
Adele FramerSurvivingAntidepressants.org, San Francisco, CA, USA.
Michael P HengartnerDepartment of Applied Psychology, Zurich University of Applied Sciences, Zurich, Switzerland.
Anders SørensenCopenhagen Trial Unit, Centre for Clinical Intervention Research, Capital Region of Denmark, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
David TaylorSouth London and Maudsley NHS Foundation Trust, London, UK.ORCID 0000-0002-2557-1710
Copenhagen University Hospital · DKKing's College London · GBNorth East London NHS Foundation Trust · GBZHAW Zurich University of Applied Sciences · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adaptation of the brain to the presence of a drug predicts withdrawal on cessation. The outcome of adaptation is often referred to as 'physical dependence' in pharmacology, as distinct from addiction, although these terms have unfortunately become conflated in some diagnostic guides. Physical dependence to antidepressants may occur in some patients, consistent with the fact that some patients experience withdrawal effects from these medications. It is thought that longer duration of use, higher dose and specific antidepressants affect the risk of antidepressant withdrawal effects as they might cause greater adaptation of the brain. We searched PubMed for relevant systematic reviews and other relevant analyses to summarise existing data on determinants of antidepressant withdrawal incidence, severity and duration. Overall, data were limited. From survey data, increased duration of use was associated with an increased incidence and severity of withdrawal effects, consistent with some evidence from data provided by drug manufacturers. Duration of use may be related to duration of withdrawal effects but data are heterogenous and sparse. Serotonin and noradrenaline reuptake inhibitors and paroxetine are associated with higher risks than other antidepressants, though data for some antidepressants are lacking. Higher doses of antidepressant has some weak association with an increased risk of withdrawal, with some ceiling effects, perhaps reflecting receptor occupancy relationships. Past experience of withdrawal effects is known to predict future risk. Based on these data, we outline a preliminary rubric for determining the risk of withdrawal symptoms for a particular patient, which may have relevance for determining tapering rates. Given the limited scope of the current research, future research should aim to clarify prediction of antidepressant withdrawal risk, especially by examining the risk of withdrawal in long-term users of medication, as well as the severity and duration of effects, to improve the preliminary tool for predictive purposes. Further research into the precise adaptations in long-term antidepressant use may improve the ability to predict withdrawal effects for a particular patient.

Indexed as

Antidepressive AgentsSelective Serotonin Reuptake InhibitorsHumansAntidepressive AgentsSelective Serotonin Reuptake Inhibitors

Identifiers

PMID36513909
PMCPMC9911477
OpenAlexW4311302465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.